This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Merck will showcase results in innovative solutions in HIV treatment and prevention
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Subscribe To Our Newsletter & Stay Updated
